01:30 PM EDT, 07/03/2025 (MT Newswires) -- Liminatus Pharma ( LIMN ) said Thursday it formed a research and development consortium with Samda Biolab and Innocs AI to advance a blood-based diagnostic kit for early detection of pancreatic cancer.

As part of the consortium, Liminatus Pharma ( LIMN ) said it would contribute clinical development expertise and regulatory guidance and would lead the regulatory process through both US Food and Drug Administration or FDA and the Korean Ministry of Food and Drug Safety.

The company will also oversee the acquisition of larger clinical datasets essential for regulatory submissions, and prior to a FDA filing, Liminatus said it intends to complete internal approval processes to support a deal covering investment, commercialization, and a go-to-market strategy.

LIMN shares closed 2.3% higher Thursday.

Price: 9.02, Change: +0.21, Percent Change: +2.38